Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Amgen Inc

AMGN
Current price
272.54 USD +1.66 USD (+0.61%)
Last closed 272.45 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 145 809 244 160 USD
Yield for 12 month -4.34 %
Week
Month
Year
AMGN
21.11.2021 - 28.11.2021

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

Analytics

WallStreet Target Price

277.83 USD

P/E ratio

19.3777

Dividend Yield

3.13 %

Current Year

+26 323 000 000 USD

Last Year

+25 979 000 000 USD

Current Quarter

+6 903 000 000 USD

Last Quarter

+6 986 000 000 USD

Current Year

+19 917 000 000 USD

Last Year

+19 525 000 000 USD

Current Quarter

+5 097 000 000 USD

Last Quarter

+5 173 000 000 USD

Key Figures AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 13 301 000 192 USD
Operating Margin TTM 38.94 %
PE Ratio 19.3777
Return On Assets TTM 7.86 %
PEG Ratio 2.2206
Return On Equity TTM 133.8 %
Wall Street Target Price 277.83 USD
Revenue TTM 26 833 000 448 USD
Book Value 14.31 USD
Revenue Per Share TTM 50.16 USD
Dividend Share 8.33 USD
Quarterly Revenue Growth YOY 3.8 %
Dividend Yield 3.13 %
Gross Profit TTM 19 917 000 000 USD
Earnings Share 14.06 USD
Diluted Eps TTM 14.06 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -19.1 %
Profit Margin 28.2 %

Dividend Analytics AMGN

Champion - 10+ consecutive years of dividend increases

Dividend growth over 5 years

69 %

Continuous growth

11 years

Payout Ratio 5 years average

54 %

Dividend History AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 8.52
Ex Dividend Date 16.11.2023
Forward Annual Dividend Yield 3.13 %
Last Split Factor 2:1
Payout Ratio 47.25 %
Last Split Date 22.11.1999
Dividend Date 08.12.2023

Stock Valuation AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 19.3777
Forward PE 13.9276
Enterprise Value Revenue 6.3935
Price Sales TTM 5.434
Enterprise Value EBITDA 11.5745
Price Book MRQ 19.0479

Financials AMGN

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators AMGN

For 52 weeks

208.37 USD 286.21 USD
50 Day MA 270.11 USD
Shares Short Prior Month 6 411 341
200 Day MA 246.36 USD
Short Ratio 2.66
Shares Short 6 773 456
Short Percent 1.27 %